Completed PHASE2 INTERVENTIONAL 2-arm NCT02327754

Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout (UPWARD)

Effect of Topiroxostat on Urinary Albumin Excretion in Patients With eARly Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout: a Randomized, Placebo-controlled, Double-blind Phase 2a Trial (UPWARD).

Sponsor: Fuji Yakuhin Co., Ltd.

Conditions Diabetic Nephropathy

Interventions Placebo BID, (Oral daily dosing for 28 weeks) Topiroxostat BID, (Oral daily dosing for 28 weeks)

Updated 6 times since 2017 Last updated: Apr 10, 2017 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diabetic Nephropathy and is currently completed. Fuji Yakuhin Co., Ltd. leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
May 2017 — Jun 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fuji Yakuhin Co., Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.

Data source: Sanwa Kagaku Kenkyusho Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nagoya, Japan